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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER2263Inflammation in Atrial FibrillationYutao Guo, Gregory Y. H. Lip, Stavros Apostolakis
Atrial fibrillation (AF) is associated with increased risk for stroke and systemic embolism.
Guo and colleagues review the evidence linking inflammation to the initiation and
perpetuation of AF and AF-related thrombosis. Proposed mechanisms linking inflammation
and the pro-thrombotic AF state include endothelial activation/damage, production of tissue
factor from monocytes, increased platelet activation, and increased expression of fibrinogen.
The utility of inflammatory markers for risk stratification and for identifying AF related
pathways is also reviewed.VIEWPOINT AND COMMENTARY VIEWPOINT AND COMMENTARY
2271Estimating the Costs and Benefits of
ECG Screening of Athletes in the United StatesAmir Halkin, Arie Steinvil, Raphael Rosso, Arnon Adler, Uri Rozovski, Sami Viskin
A single study from Italy suggests that mandatory ECG screening of athletes reduces their
risk of sudden cardiac death (SCD). Based on that study, ECG screening is endorsed by the
European Society of Cardiology (ESC), although not by the American Heart Association
(AHA). Halkin and colleagues developed a cost-projection model based on the Italian study
extrapolating the data for the United States. Based on this model, a 20-year program of ECG
screening of young competitive athletes in the United States would cost between $51 and $69
billion and would save 4,813 lives. The cost per live saved is computed to range between
$10.6 and $14.4 million. These results suggest that even if the benefits seen in the Italian
Study were also found in the United States, the cost per life saved would be enormous.
Editorial Comment: Antonio Pelliccia, page 2277(continued on page A-22)
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2280Worse Outcomes for Patients With Diabetes
Following Percutaneous Coronary StentingWilliam B. Hillegass, Manesh R. Patel, Lloyd W. Klein, Hitinder S. Gurm, J. Matthew Brennan,
Kevin J. Anstrom, David Dai, Eric L. Eisenstein, Eric D. Peterson, John C. Messenger, Pamela S. Douglas
Hillegass and colleagues used data from the National Cardiovascular Data Registry (NCDR)
to determine the efficacy of percutaneous coronary stenting in elderly patients, particularly
those with diabetes. Data from 405,679 patients 65 years of age, one-third of whom had
diabetes, was collected and linked to Medicare inpatient claims data. During a median 18
months follow-up, patients with diabetes were at twice the risk of death and myocardial
infarction compared to nondiabetics. They were also more likely to undergo additional
revascularization procedures and to be hospitalized for bleeding. These data quantitatively
define the expected 3- to 4-year outcomes of death, myocardial infarction, additional
revascularization, and subsequent hospitalization for bleeding in older diabetics undergoing
stent implantation.INTERVENTIONAL CARDIOLOGY2290SES Best BA for Infrapopliteal StenosisDierk Scheinert, Konstantinos Katsanos, Thomas Zeller, Renate Koppensteiner, Philip Commeau,
Marc Bosiers, Hans Krankenberg, Iris Baumgartner, Dimitris Siablis, Johannes Lammer,
Mariella Van Ransbeeck, Ayesha C. Qureshi, Hans-Peter Stoll, on behalf of the ACHILLES Investigators
The Achilles trial investigated the efficacy and safety of sirolimus-eluting stents (SES)
compared to balloon angioplasty only in patients with symptomatic infrapopliteal arterial
disease. A total of 200 patients were randomized to infrapopliteal stenting with SES or
balloon angioplasty (BA). The primary endpoint was in-segment binary restenosis. At 1 year,
22% of patients in the SES arm and 42% in the BA arm reached the primary endpoint;
vessel patency was 75% for SES versus 57% for PTA. The benefits in diabetics were
especially significant. Implantation of SES may offer a promising therapeutic option for
treatment of infrapopliteal peripheral arterial disease.(continued on page A-28)
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2296Comparison of the Prognosis of CK-MB
Elevations Caused by Spontaneous and PCI-Related MIsSergio Leonardi, Laine Thomas, Megan L. Neely, Pierluigi Tricoci, Renato D. Lopes, Harvey D. White,
Paul W. Armstrong, Robert P. Giugliano, Elliott M. Antman, Robert M. Califf, L. Kristin Newby,
Kenneth W. Mahaffey
Leonardi and colleagues compared prognostic value of varying creatine kinase (CK)-MB
thresholds after myocardial infarction (MI) related to percutaneous coronary intervention
(PCI) (“procedural MI”) or spontaneous MI. Patients from 2 trials were examined with a
primary endpoint of 1-year all-cause mortality from 24 h post-PCI. Adjusted hazard ratios
for 1-year death were 1.39 for procedural MI and 5.37 for spontaneous MI. The CK-MB
threshold for procedural MI that achieved the same prognosis as spontaneous MI was 27.7 
upper limit of normal (ULN) for CK-MB. These results show that the current enzymatic
definition of procedural MI (CK-MB 3  ULN) is less strongly associated with death than
that of spontaneous MI.HEART FAILURE2305SQ BNP Infusions May Be Useful for Chronic Systolic HFHorng H. Chen, James F. Glockner, John A. Schirger, Alessandro Cataliotti, Margaret M. Redfield,
John C. Burnett Jr
Chen and colleagues performed a randomized, double-blind, placebo-controlled proof-of-
concept study comparing 8 weeks of subcutaneous (SQ) B-type natriuretic peptide (BNP)
infusions to placebo in 40 patients with ejection fraction 35% and New York Heart
ssociation functional class II to III heart failure (HF). Eight weeks of SQ BNP resulted in
reduction of left ventricular (LV) systolic and diastolic volume index and LV mass index as
easured by magnetic resonance imaging. There was significantly greater improvement of
innesota Living with Heart Failure (MLHF) score, LV filling pressure, and left atrial
olume index. In this pilot proof of concept study, chronic protein therapy with SQ BNP
esulted in several improvements and further, larger studies appear warranted.
ditorial Comment: Tariq Ahmad, G. Michael Felker, page 2313(continued on page A-30)
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ECARDIAC IMAGING2316CMRA Provides Prognostic Information in Patients With Suspected CADYeonyee E. Yoon, Kakuya Kitagawa, Shingo Kato, Masaki Ishida, Hiroshi Nakajima, Tairo Kurita,
Masaaki Ito, Hajime Sakuma
Yoon and colleagues sought to determine whether whole-heart coronary magnetic resonance
angiography (CMRA) can predict cardiac events in patients with suspected coronary artery
disease (CAD). A total of 207 patients underwent noncontrast enhanced free-breathing
whole-heart CMRA and were followed for clinical events. The presence of significant
coronary stenosis (50% diameter reduction) was visually determined on sliding thin-MIP
images. Cox regression analysis showed that the presence of significant stenosis on CMRA
was associated with a 20-fold hazard increase for subsequent cardiac events. Whole-heart
MRA appears to be useful for predicting the risk for cardiac events in patients with
uspected CAD.ditorial Comment: Warren J. Manning, Raymond H. Chan, page 2323HEART VALVE DISEASE
2325Incidence and Clinical Outcomes of Asymptomatic
Patients With Severe AS and LV Systolic DysfunctionDanielle M. Henkel, Joseph F. Malouf, Heidi M. Connolly, Hector I. Michelena, Maurice E. Sarano,
Hartzell V. Schaff, Christopher G. Scott, Patricia A. Pellikka
Henkel and colleagues performed a retrospective chart review to determine the prevalence,
characteristics, and outcomes of asymptomatic left ventricular (LV) systolic dysfunction in
patients with severe aortic stenosis (AS). Of the 9,940 patients with severe AS, only
43 (0.4%) patients had asymptomatic LV dysfunction, while 24% has symptomatic LV
dysfunction. One-half of these patients developed symptoms during follow-up, and half died
within 5 years. After age/gender adjustment, there was no survival advantage with aortic valve
replacement. Despite an asymptomatic clinical status, patients with severe AS and LV
ejection fraction 50% have a poor prognosis, with or without AVR.
